{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:29:49Z","timestamp":1783200589522,"version":"3.54.6"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00432-022-04252-2","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T11:02:54Z","timestamp":1662030174000},"page":"4141-4148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5147-4431","authenticated-orcid":false,"given":"Mutlu","family":"Hizal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nail","family":"Paksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Mustafa","family":"Atc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda","family":"Kahraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadettin","family":"K\u0131l\u0131\u00e7kap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz Can","family":"G\u00fcven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Keskink\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Ayhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6nder","family":"Eren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Nihan Akko\u00e7","family":"Mustafayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eebnem","family":"Yaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ertu\u011frul","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130smail","family":"Ert\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkan","family":"\u00d6zcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baran","family":"Akag\u00fcnd\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011fba Ak\u0131n","family":"Telli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asude","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Necdet","family":"\u00dcskent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naziyet K\u00f6se","family":"Baytem\u00fcr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"G\u00fclmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Din\u00e7er","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teoman","family":"\u015eakalar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hac\u0131","family":"Arak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Murat","family":"Tatl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakup","family":"Erg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naziye","family":"Ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7a\u011flar","family":"\u00dcnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Alpaslan","family":"\u00d6zg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent","family":"Yal\u00e7\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lhan","family":"\u00d6ztop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efnan","family":"Alg\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Sakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Ayd\u0131ner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perran Fulden","family":"Yumuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali Nahit","family":"\u015eendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"issue":"9","key":"4252_CR1","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s00432-021-03546-1","volume":"147","author":"B Bilgin","year":"2021","unstructured":"Bilgin B, \u015eendur MAN, Y\u00fccel \u015e, Hizal M, G\u00fcner G, Aky\u00fcrek N et al (2021) The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement. J Cancer Res Clin Oncol 147(9):2637\u20132643","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"4252_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/gtmb.2019.0038","volume":"23","author":"Y He","year":"2019","unstructured":"He Y, Gong R, Sun LY, Zhang ZC, Liu XY, Shao Q et al (2019) The percentage of anaplastic lymphoma kinase-positive tumor cells has clinical implications for patients with non-small cell lung cancer. Genet Test Mol Biomark 23(8):589\u2013597","journal-title":"Genet Test Mol Biomark"},{"issue":"1","key":"4252_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12957-021-02386-0","volume":"19","author":"F Jiang","year":"2021","unstructured":"Jiang F, Wang C, Yang P, Sun P, Liu J (2021) Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study. World J Surg Oncol 19(1):278","journal-title":"World J Surg Oncol"},{"issue":"5","key":"4252_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1097\/JTO.0b013e3182111461","volume":"6","author":"Y Koh","year":"2011","unstructured":"Koh Y, Kim DW, Kim TM, Lee SH, Jeon YK, Chung DH et al (2011) Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. J Thorac Oncol 6(5):905\u2013912","journal-title":"J Thorac Oncol"},{"issue":"18","key":"4252_CR5","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG et al (2010) Anaplastic lymphoma kinase inhibition in non\u2013small-cell lung cancer. N Engl J Med 363(18):1693\u20131703","journal-title":"N Engl J Med"},{"issue":"3","key":"4252_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cllc.2015.09.002","volume":"17","author":"YY Lei","year":"2016","unstructured":"Lei YY, Yang JJ, Zhang XC, Zhong WZ, Zhou Q, Tu HY et al (2016) Anaplastic lymphoma kinase variants and the percentage of ALK-positive tumor cells and the efficacy of crizotinib in advanced NSCLC. Clin Lung Cancer 17(3):223\u2013231","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"4252_CR7","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW et al (2020) Updated overall survival and final progression-free survival data for patients with treatment-naive advanced <em>ALK<\/em>-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 31(8):1056\u20131064","journal-title":"Ann Oncol"},{"issue":"9","key":"4252_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377(9):829\u2013838","journal-title":"N Engl J Med"},{"issue":"16","key":"4252_CR9","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1158\/1078-0432.CCR-09-0802","volume":"15","author":"SJ Rodig","year":"2009","unstructured":"Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA et al (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15(16):5216\u20135223","journal-title":"Clin Cancer Res"},{"issue":"26","key":"4252_CR10","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","volume":"27","author":"AT Shaw","year":"2009","unstructured":"Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27(26):4247\u20134253","journal-title":"J Clin Oncol"},{"issue":"25","key":"4252_CR11","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim D-W, Nakagawa K, Seto T, Crin\u00f3 L, Ahn M-J et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385\u20132394","journal-title":"N Engl J Med"},{"issue":"23","key":"4252_CR12","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371(23):2167\u20132177","journal-title":"N Engl J Med"},{"issue":"9","key":"4252_CR13","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/annonc\/mdy242","volume":"29","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ho SN, Varella-Garcia M, Iafrate AJ, Solomon BJ, Shaw AT et al (2018) Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. Ann Oncol 29(9):1964\u20131971","journal-title":"Ann Oncol"},{"key":"4252_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cancergen.2019.12.003","volume":"241","author":"GA Toruner","year":"2020","unstructured":"Toruner GA, Tang Z, Tang G, Medeiros LJ, Hu S (2020) Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors. Cancer Genet 241:57\u201360","journal-title":"Cancer Genet"},{"issue":"9","key":"4252_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139264","volume":"10","author":"F Zito Marino","year":"2015","unstructured":"Zito Marino F, Liguori G, Aquino G, La Mantia E, Bosari S, Ferrero S et al (2015) Intratumor heterogeneity of ALK-rearrangements and homogeneity of EGFR-mutations in mixed lung adenocarcinoma. PLoS\u00a0One 10(9):e0139264","journal-title":"PLoS\u00a0One"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04252-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04252-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04252-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T14:03:01Z","timestamp":1689429781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04252-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4252"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04252-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"22 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}